Information: This is an outdated version of the data model. You can find a Versions overview via Versions on the left. You can find the newest Version by clicking here.
Information:
Error:
ID
35265
Description
Study ID: 101222 Clinical Study ID: 101222 Study Title: Study to demonstrate the non-inferiority of GSK Biologicals' DTPw-HBV/Hib Kft. vaccine compared to GSK Biologicals' Tritanrix™-HepB/Hiberix™ vaccine and to separate administration of DTPw-HBV Kft. and Hiberix™ vaccines with respect to the immunogenicity of all antigens, when administered to healthy infants. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine (KFT) Trade Name:Zilbrix/Hib Study Indication: Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis
Keywords
Versions (2)
- 2/25/19 2/25/19 -
- 2/28/19 2/28/19 -
Copyright Holder
GSK group of companies
Uploaded on
February 25, 2019
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Immunogenicity of TPw-HBV/Hib Kft. Vaccine in healthy infants
Similar models
Visit 1
- StudyEvent: ODM
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Visit Number
Item
Visit Number
integer
Subject Number
Item
Subject Number
integer
Planned administration/administration of a vaccine not foreseen by the study protocol
Item
Planned administration/administration of a vaccine not foreseen by the study protocol within 30 days of the first dose of the combined DTPw-HepB vaccine or DTPw-HepB/Hib vaccine, with the exception of oral poliovirus vaccine (OPV).
boolean
EliminationCriteriaConcomitantMedication
Item
Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) during the study period.
boolean
EliminationCriteriaImmunosuppressants
Item
Chronic administration (defined as more than 14 days) of immunosuppressants or other immunomodifying drugs during the study period. (For corticostreoids, this will mean prednisone, or equivalent, >= 0.5 mg/kg/day. Inhaled and topical steroids are allowed).
boolean
EliminationCriteriaPriorVaccination
Item
Hepatitis B vaccine received after the first 72 hours of life.
boolean
EliminationCriteriaBacilleCalmette-Guérin
Item
Bacille Calmette-Guérin (BCG) vaccine given after the first 2 weeks of life.
boolean
EliminationCriteriaPreviousVaccination
Item
Previous vaccination against diphtheria, tetanus, pertussis or Haemophilus influenzae or hepatitis B (except if indicated in the group allocation).
boolean
EliminationCriteriaHistoryDiphteria
Item
History of or known exposure to diphtheria, tetanus, pertussis, hepatitis B or Hib diseases.
boolean
EliminationCriteriaImmunodeficientCondition
Item
Any confirmed immunodeficient condition, based on medical history and physical examination (no laboratory testing is required at study entry).
boolean
EliminationCriteriaAllergies
Item
History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
boolean
EliminationCriteriaImmunoglobulinsAdministration
Item
Administration of immunoglobulins and/ or any blood products during the study period.
boolean
EliminationCriteriaConcomitantVaccines
Item
Use of any investigational or non-registered drug or vaccine other than the study vaccine(s) during the study period.
boolean
EliminationCriteriaChronicImmunosuppressantsAdministration
Item
Chronic administration (defined as more than 14 days) of immunosuppressants or other immunomodifying drugs during the study period. (For corticostreoids, this will mean prednisone, or equivalent, = 0.5 mg/kg/day. Inhaled and topical steroids are allowed).
boolean
EliminationCriteriaPlannedConcomitantVaccineAdministration
Item
Planned administration/ administration of a vaccine not foreseen by the study protocol during the period from 30 days before each dose of vaccine and ending 30 after the last dose of vaccine, with the exception of OPV.
boolean
EliminationCriteriaImmunoglobulinsAdministration
Item
Administration of immunoglobulins and/or any blood products during the study period.
boolean
EliminationCriteriaImmunodeficientCondition
Item
Any confirmed immunodeficient condition, based on medical history and physical examination (no laboratory testing required at study entry).
boolean
ContraindicationsAnaphylacticReaction
Item
Anaphylactic reaction following the administration of vaccines.
boolean
ContraindicationsHypersensitivity
Item
Known hypersensitivity to any component of the vaccine, or subjects having shown signs of hypersensitivity after previous administration of diphtheria, tetanus, pertussis, hepatitis B or Hib vaccines
boolean
ContraindicationsEncephalopathy
Item
Encephalopathy (not due to another identifiable cause).
boolean
ContraindicationsDisease
Item
Acute disease at the time of vaccination. (Acute disease is defined as the presence of a moderate or severe illness with or without fever. All vaccines can be administered to persons with a minor illness such as diarrhea, mild upper respiratory infection with or without low-grade febrile illness, i.e. axillary temperature < 37.5 °C or rectal temperature < 38 °C.
boolean
ContraindicationsTemperature
Item
Axillary or oral temperature = 37.5 °C or Rectal temperature = 38 °C at the time of vaccination.
boolean
PrecautionsFever
Item
Fever = 40.0 °C (preferable axillary temperature or oral temperature) within 48 hours of vaccination, not due to another identifiable cause.
boolean
PrecautionsShock
Item
Collapse or shock-like state (hypotonic-hyporesponsive episode) within 48 hours of vaccination.
boolean
PrecautionsCrying
Item
Persistent crying lasting = 3 hours, occurring within 48 hours of vaccination
boolean
PrecautionsConvulsions
Item
Convulsions with or without fever, occurring within 3 days of vaccination.
boolean
CL Item
A history of febrile convulsions, a family history of convulsions, a family history of Sudden Infant Death (1)
CL Item
Syndrome (SIDS) and a family history of an adverse event following Tritanrix™-HepB vaccination do not (Syndrome (SIDS) and a family history of an adverse event following Tritanrix™-HepB vaccination do not)
CL Item
constitute contraindications. (constitute contraindications.)
CL Item
As with all injectable vaccines, appropriate medical treatment should always be readily available in case of (2)
CL Item
anaphylactic reactions following the administration of the vaccine. For this reason, the vaccinee should (anaphylactic reactions following the administration of the vaccine. For this reason, the vaccinee should)
CL Item
remain under medical supervision for 30 minutes after vaccination. (remain under medical supervision for 30 minutes after vaccination.)
CL Item
DTPw-HBV should be administered with caution to subjects with thrombocytopenia or a bleeding disorder (3)
CL Item
since bleeding may occur following an intramuscular administration to these subjects. (since bleeding may occur following an intramuscular administration to these subjects.)
CL Item
DTPw-HBV should under no circumstances be administered intravenously. (DTPw-HBV should under no circumstances be administered intravenously.)
I certify that Informed Consent has been obtained prior to any study procedure.
Item
I certify that Informed Consent has been obtained prior to any study procedure.
boolean
Informed Consent Date :
Item
Informed Consent Date :
date
CenterNumber
Item
Center number :
integer
BirthDate
Item
Date of birth :
date
CL Item
Male (1)
CL Item
Female (2)
CL Item
Black (1)
CL Item
Arabic/North African (2)
CL Item
White/Caucasian (3)
CL Item
East & South East Asian (4)
CL Item
South Asian (5)
CL Item
American Hispanic (6)
CL Item
Japanese (7)
CL Item
Other (8)
OtherRace
Item
If Other, please specify
text
EligibilityCheckQuestion
Item
Did the subject meet all the entry criteria?
boolean
Item
Tick the boxes corresponding to any of the inclusion criteria the subject failed
text
Code List
Tick the boxes corresponding to any of the inclusion criteria the subject failed
CL Item
Born to a mother known to be seronegative for HBsAg (documented laboratory result of HBsAgassay from a maternal blood sample is available). (1)
CL Item
Written informed consent obtained from the parent or guardian of the subject. (2)
CL Item
Free of obvious health problems as established by medical history and clinical examination (3)
CL Item
before entering into the study. (before entering into the study.)
CL Item
Born after a normal gestation period (between 36 and 42 weeks). (4)
CL Item
A male or female less than or equal to 3 days (72 hours) of age at the time of the birth dose of (5)
CL Item
Hepatitis B vaccination, if indicated for the group. (Hepatitis B vaccination, if indicated for the group.)
CL Item
Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) since birth, or planned use during the study period. (6)
Item
Tick the box corresponding to any of the exclusion criteria that disqualified the subject from entry.
text
Code List
Tick the box corresponding to any of the exclusion criteria that disqualified the subject from entry.
CL Item
Use of any investigational or non-registered product (drug or vaccine) other than the study (1)
CL Item
vaccine(s) since birth, or planned use during the study period. (vaccine(s) since birth, or planned use during the study period.)
CL Item
Any confirmed immunodeficient condition, based on medical history and physical (2)
CL Item
examination (no laboratory testing is required at study entry). (examination (no laboratory testing is required at study entry).)
CL Item
A family history of congenital or hereditary immunodeficiency. (3)
CL Item
Major congenital defects or serious chronic illness. (4)
CL Item
History of any neurologic disorders or seizures. (5)
CL Item
Administration of immunoglobulins and/or any blood products since birth or planned (6)
CL Item
administration during the study period. (administration during the study period.)
CL Item
Acute disease at the time of enrolment. (Acute disease is defined as the presence of a (7)
CL Item
moderate or severe illness with or without fever. All vaccines can be administered to (moderate or severe illness with or without fever. All vaccines can be administered to)
CL Item
persons with a minor illness such as diarrhea, mild upper respiratory infection with or without (persons with a minor illness such as diarrhea, mild upper respiratory infection with or without)
CL Item
low-grade febrile illness, i.e., axillary temperature < 37.5 °C or rectal temperature < 38 °C). (low-grade febrile illness, i.e., axillary temperature < 37.5 °C or rectal temperature < 38 °C).)
CL Item
Other conditions which in the opinion of the investigator may potentially interfere with (8)
CL Item
interpretation of study outcomes. (interpretation of study outcomes.)
CL Item
Hepatitis B vaccination given at birth outside the study. (9)
TreatmentNumber
Item
Record treatment number
integer
VaccinationAtBirth
Item
Has the Engerix™-B vaccine been administered at birth ?
boolean